Group One Trading’s Crinetics Pharmaceuticals CRNX Stock Holding History

Group One Trading’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100	Closed	-$4.66K	–	7817
2025 Q4	$4.66K	Sell	100 -3,600	-97%	-$160K	﹤0.01%	7212
2025 Q3	$154K	Buy	+3,700	New	+$118K	﹤0.01%	4943
2025 Q2	–	Sell	-500	Closed	-$16.8K	–	8015
2025 Q1	$16.8K	Buy	+500	New	+$18.7K	﹤0.01%	5936
2024 Q2	–	Sell	-5,300	Closed	-$248K	–	6833
2024 Q1	$248K	Buy	5,300 +900	+20%	+$35.2K	﹤0.01%	3365
2023 Q4	$157K	Sell	4,400 -16,600	-79%	-$509K	﹤0.01%	4081
2023 Q3	$625K	Buy	+21,000	New	+$433K	﹤0.01%	2703

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Group One Trading's CRNX Position: Q3 2025 in Review

Group One Trading sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2025, closing a stake of 2,796 shares — an estimated $89.4K sold.

Group One Trading first reported a position in CRNX in Q4 2021 and held it in 7 quarters. The position peaked at $245K in Q3 2023. 225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

Group One Trading reported no remaining Crinetics Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Group One Trading sold 2,796 Crinetics Pharmaceuticals shares in Q3 2025, an estimated $89.4K.
Group One Trading first reported a position in Crinetics Pharmaceuticals in Q4 2021 and held it in 7 quarters.
Group One Trading's Crinetics Pharmaceuticals position peaked at $245K in Q3 2023.
225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on Group One Trading's 13F filing for Q3 2025, filed 12 Nov 2025.